Veteran Bank Revises Rocket Lab Stock Target for 2027
Rocket Lab (RKLB) shares dropped 10% after KeyBanc cut its price target to $100 from $135, citing a delay in Neutron rocket debut to 2027 due to manufacturing issues. KeyBanc kept an Overweight rating but lowered forecasts due to the delay and reduced valuation multiples in space stocks.
How this was made
The 30-second read
Why it matters
The target reduction and launch delay are the primary catalysts for the immediate price move.
Market read
RKLB shares fell ~10% on the news; traders may adjust positions based on the revised outlook.
What to watch
Potential downstream contracts or government subsidies that could offset the launch delay.
Background
KeyBanc retained an Overweight rating despite the target cut, indicating belief in long‑term upside.
Ticker impact
KeyBanc cut RKLB's price target to $100 and noted a delay of the Neutron rocket to 2027, causing a ~10% share drop.
downward pressure as investors price in the delayed revenue and reduced target
The analyst downgrade and concrete schedule slip are fresh, material news that directly moved the stock.
Market effects
The delay may damp enthusiasm for the broader small‑cap space‑flight sector.
Limited to U.S. investors focused on commercial space stocks.
Minimal; impact confined to RKLB and peers.
Counterpoint
If the Neutron launch eventually succeeds, the stock could rebound sharply, making the dip a buying opportunity.
Key entities
- analystKeyBanc
Equity research firm that lowered RKLB's price target.
- companyRocket Lab
Space launch provider whose Neutron rocket schedule slipped.
